European Medicines Agency's Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA

Biogen Idec BIIB announced today that FAMPYRA has been granted a positive opinion for conditional approval from the European Medicines Agency's Committee for Medicinal Products for Human Use. Based on the CHMP recommendation, Biogen Idec expects that a marketing authorisation for FAMPYRA should be granted within 67 days.